Bibliothek - CAR-T

CAR-T-Academy Literatur

Titel: Long-Term (4- and 5-Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel in Patients with Refractory Large B-Cell Lymphoma
Autor: Caron A. Jacobson et al.
Link: Download Poster (PDF)
Schlagwörter: CAR-T; DLBCL; PMBCL; tFL; Efficacy; Survival; Axi-Cel; ZUMA

Titel: Real World Evidence of Axicabtagene Ciloleucel (Axi Cel) for the Treatment of Large B Cell Lymphoma in the United States
Autor: Caron A. Jacobson et al.
Link: Download Poster (PDF)
Schlagwörter: CAR-T; DLBCL; PMBCL; tFL; Efficacy; Real world; Axi-Cel; ZUMA

Titel: Outcomes With KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 Who Had Progression of Disease Within 24 Months of Diagnosis (POD24)
Autor: Michael L. Wang et al.
Link: Download Poster (PDF)
Schlagwörter: CAR-T; MCL Efficacy; POD24; KTE-X19; ZUMA

Titel: Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Autor: Caron A. Jacobson et al.
Link: https://doi.org/10.1200/JCO.19.02103
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Real world; Transplant; Axicabtagene; ZUMA

Titel: Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Autor: Chelsea C. Pinnix et al.
Link: https://doi.org/10.1182/bloodadvances.2020001837
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Characteristics; Transplant; Axicabtagene; Tiseagenlecleucel; ZUMA; Juliet; Manufacturing; Bridging

Titel: Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma
Autor: Olalekan O. Oluwole et al.
Link: https://doi.org/10.1016/j.bbmt.2020.06.008
Schlagwörter: DLBCL; PMBCL; Efficacy; Toxicity; Management; Characteristics; Transplant; Axicabtagene; Tisagenlecleucel; ZUMA; Juliet; YESCARTA; Kymriah; Manufacturing; Bridging

Titel: Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Autor: Loretta J. Nastoupil et al.
Link: https://doi.org/10.1200/JCO.19.02104
Schlagwörter: DLBCL; PMBCL; Efficacy; Toxicity; Management; Real-World; Characteristics; Transplant; Axicabtagene; Tisagenlecleucel; ZUMA; Juliet; YESCARTA; Manufacturing; Bridging

Titel: Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T cell therapy: position statement of the Austrian CAR-T Cell Network
Autor: Hildegard T. Greinix et al.
Link: https://doi.org/10.1007/s12254-020-00582-4
Schlagwörter: DLBCL; PMBCL; Toxicity; Management; Real-World; Transplant; Axicabtagene; Tisagenlecleucel; YESCARTA; Kymriah

Titel: Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
Autor: Austin J. Sim et al.
Link: https://doi.org/10.1016/j.ijrobp.2019.05.065
Schlagwörter: DLBCL; tFL; Toxicity; Management; Real-World; Transplant; Characteristics; Axicabtagene; Tisagenlecleucel; YESCARTA; Kymriah; ZUMA; Juliet; Bridging

Titel: CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
Autor: Georg Hopfinger, Ulrich Jäger, Nina Worel
Link: http://dx.doi.org/10.1097/HS9.0000000000000185
Schlagwörter: DLBCL; PMBCL; tFL; Toxicity; Management; Transplant; Characteristics; Axicabtagene; Tisagenlecleucel; Lisocabtagene; YESCARTA; Kymriah; ZUMA; Juliet; TRANSCEND; Bridging

Titel: The long road to the first FDA approved gene therapy: chimeric antigen receptor T cells targeting CD19
Autor: Peter Braendstrup, Bruce L. Levine, Marco Ruella
Link: https://doi.org/10.1016/j.jcyt.2019.12.004
Schlagwörter: Axicabtagene; Tisagenlecleucel; Manufacturing

Titel: Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
Autor: Peter A. Riedell and Michael R. Bishop
Link: http://doi.org/10.1177/2040620720902899
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Real-World; Characteristics; Axicabtagene; YESCARTA; ZUMA; Bridging

Titel: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Autor: Frederick L Locke
Link: http://dx.doi.org/10.1016/S1470-2045(18)30864-7
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Characteristics; Axicabtagene; Tisagenlecleucel; Lisocabtagene; ZUMA; Juliet; Transcend; Bridging

Titel: CAR-T design: Elements and their synergistic function
Autor: Jayapriya Jayaramana et al.
Link: https://doi.org/10.1016/j.ebiom.2020.102931
Schlagwörter: Chimeric antigen receptor, CAR-T Immunotherapy, Cancer, Cell engineering, Synthetic biology

Titel: Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies (blood advances)
Autor: David Sermer et al.
Link: https://doi.org/10.1182/bloodadvances.2020002118
Journal: blood advances
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Real world; Transplant; Axicabtagene; Tisagenlecleucel

Titel: Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Autor: Frederick L. Locke et al.
Link: https://doi.org/10.1182/bloodadvances.2020002394
Journal: blood advances
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Characteristics; Transplant; Axicabtagene; Tiseagenlecleucel; ZUMA; Juliet; Manufacturing; Bridging

Titel: Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Autor: Daniel B. Rubin et al.
Link: https://doi.org/10.1093/brain/awz053
Journal: Brain
Schlagwörter: DLBCL; Toxicity; Management; Axicabtagene; Tisagenlecleucel; neurologic toxicity, ICANS

Titel: EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
Autor: Irene Papadouli et al.
Link: https://dx.doi.org/10.1634/theoncologist.2019-0646
Journal: The Oncologist
Schlagwörter: DLBCL; PMBCL; Efficacy; Toxicity; Management; Axicabtagene; ZUMA; YESCARTA

Titel: Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
Autor: Felix Korell et al.
Link: https://doi.org/10.3390/cells9051225
Journal: cells
Schlagwörter: DLBCL; PMBCL; Axicabtagene; Tisagenlecleucel; YESCARTA; Kymriah; manufacturing

Titel: Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Autor: Sattva S. Neelapu et al.
Link: https://doi.org/10.1182/blood.2019004162
Journal: letter to blood
Schlagwörter: DLBCL; tFL; Toxicity; Management; Transplant; Characteristics; Axicabtagene; YESCARTA; ZUMA

Titel: Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Autor: Pei_hsuan Chen et al
Link: http://doi.org/10.1172/jci.insight.134612
Journal: JCI insight
Schlagwörter: DLBCL; PMBCL; tFL; Toxicity; Characteristics; Axicabtagene; YESCARTA; ZUMA

Titel: Long-term survival and gradual recovery of B cells in pationes with refractory large B cell lymphoma treatet with Axicabtagene-Ciloleucel
Autor: Jacobson C. et al.
Link: Download Poster (PDF)
Schlagwörter: ASH 2020 Abstract 1187; DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Axicabtagene; ZUMA

Titel: Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Autor: Caron A. Jacobson et al.
Link: https://doi.org/10.1200/JCO.19.02103
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Real world; Transplant; Axicabtagene; ZUMA

Titel: Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Autor: Chelsea C. Pinnix et al.
Link: https://doi.org/10.1182/bloodadvances.2020001837
Schlagwörter: DLBCL; PMBCL; tFL; Efficacy; Toxicity; Management; Characteristics; Transplant; Axicabtagene; Tisagenlecleucel; ZUMA; Juliet; Manufacturing; Bridging